ArticleAnnals of nuclear medicine2026
Subcutaneous/cutaneous uptake in the cancer-affected breast on
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Subcutaneous Adipose Tissue FDG Uptake is Associated with Systemic Inflammatory Indices Independent of Primary-Tumor Metabolic Burden in Breast Cancer.Molecular imaging and biology · 2026Article
- Response to the comment on "Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT".Annals of nuclear medicine · 2026Article
- Response to the comment on "Subcutaneous/cutaneous uptake in the cancer-affected breast onAnnals of nuclear medicine · 2026Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSubcutaneous/cutaneous uptake (SCU) is occasionally observed in the cancer-affected breast, apart from the primary tumor. This study aimed to explore the prognostic value of SCU on preoperative Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (
methodsThis retrospective single-center study included patients with newly diagnosed unilateral stage I-III non-inflammatory breast cancer who underwent preoperative
resultsAmong 168 women (mean age: 55 years, range: 23-85), SCU was visually positive in 24 patients (14.3%), with high inter-reader agreement (κ = 0.76). SCU showed moderate concordance with SE (κ = 0.66). Dermal LVI was absent in all SCU-negative cases but detected in 2 of 7 SCU-positive cases (28.6%) (p = .005). Both visually positive SCU and sSUVr > 1.3 were associated with worse iDFS and OS (p < .05 for each). In multivariate analysis, sSUVr > 1.3 was associated with worse iDFS and OS (hazard ratio [HR] 2.80, p = .04; HR 5.74, p = .02, respectively).
conclusionsSCU on preoperative
Indexed as
Identifiers
41046498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.